# Tiziana Life Sciences Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Tiziana Life Sciences Ltd). ## Overview Tiziana Life Sciences Ltd is a U.S.-listed biotechnology company focused on developing antibody-based therapies, with its lead program centered on intranasal foralumab. The company is organized around clinical-stage drug development and related scientific and corporate activities, with a principal executive office in London. ## Products & services • Intranasal foralumab, a fully human anti-CD3 monoclonal antibody • Clinical development of immunology and neuroinflammation therapies • Expanded access and investigator-sponsored clinical programs • Biomarker and translational research supporting the pipeline - **Lead therapeutic candidate** (70%) — Development of intranasal foralumab and related clinical data generation. - **Clinical development programs** (20%) — Phase-based studies, expanded access use, and trial operations for pipeline assets. - **Translational biomarker research** (10%) — Imaging, proteomic, and mechanistic studies used to support clinical development. - Intranasal foralumab, a fully human anti-CD3 monoclonal antibody - Clinical development of immunology and neuroinflammation therapies - Expanded access and investigator-sponsored clinical programs - Biomarker and translational research supporting the pipeline ## Customers Tiziana does not sell a broad commercial product portfolio; its primary external stakeholders are clinical investigators, research centers, and regulatory bodies involved in drug development. Any eventual customers for approved therapies would be physicians, hospitals, and patients in the relevant specialty indications. The company's current activity is therefore driven more by trial enrollment, scientific validation, and partnering potential than by routine product sales. - **Clinical investigators and research hospitals** (primary) — They run studies, enroll patients, and generate data for foralumab and related programs. - **Academic medical centers** (primary) — They support mechanistic research, imaging, and translational science around the pipeline. - **Regulators and ethics bodies** (primary) — They review clinical evidence and govern whether the company can advance programs. - **Future specialty neurology prescribers** (emerging) — They would use an approved therapy for progressive MS or related indications. - **Patients with unmet neuroinflammatory disease needs** (emerging) — They are the end beneficiaries of the company's development programs. - Clinical investigators running studies in multiple sclerosis and neuroinflammation - Research hospitals and academic centers generating trial and biomarker data - Regulators and payers that determine approvability and future access - Future specialty physicians and patients if pipeline assets are commercialized ## Geography Tiziana is incorporated as a foreign private issuer and maintains its principal executive office in London, while also accessing U.S. capital markets through Nasdaq. Its reported scientific and corporate activity is centered in the United States, including New York conference participation and Boston-area research references. The business therefore spans a transatlantic structure: U.K.-based administration, U.S. market access, and U.S.-centric clinical and investor activity. - Principal executive office in London, United Kingdom - U.S. capital markets presence through Nasdaq listing - Scientific and investor activity centered in the United States - Clinical development references include Boston-area research institutions ## Strategy The company’s strategy is to build clinical evidence around foralumab by combining patient data, biomarker analysis, and mechanistic research in progressive multiple sclerosis. It also uses scientific conferences and investor communications to increase visibility for the program and support future development options, including potential partnering. - **Advance foralumab clinical development** (short-term) — Clinical proof-of-concept is central to value creation in a single-asset biotech model. - **Deepen biomarker and mechanistic evidence** (medium-term) — Translational evidence can differentiate the asset and support future development decisions. - **Increase external visibility and credibility** (short-term) — Conference presentations and publications can support fundraising and partnering discussions. - Advance intranasal foralumab through clinical and biomarker milestones - Use translational data to support disease-modifying claims - Strengthen visibility with scientific and investor conferences - Build evidence needed for partnership, licensing, or later-stage trials ## Risks As a clinical-stage biotechnology company, Tiziana depends on successful trial results, regulatory acceptance, and continued access to capital before any meaningful product revenue can emerge. The lead program is concentrated in a narrow set of neuroinflammatory indications, so development setbacks, enrollment delays, or weaker-than-expected data could materially reduce the company’s prospects. - **Clinical development failure** [critical] — The company's value is concentrated in foralumab, so negative efficacy or safety data would impair the pipeline. - **Regulatory and approval risk** [high] — Biologics require substantial evidence and regulators may not accept early-stage data as sufficient. - **Financing and dilution risk** [high] — Clinical-stage biotech companies typically need repeated capital raises before commercialization. - **Competitive indication risk** [medium] — Multiple sclerosis and neuroinflammation attract larger rivals with deeper clinical and commercial resources. - Single-asset concentration increases dependence on foralumab outcomes - Clinical trial results may not reproduce in larger or controlled studies - Regulatory approval risk remains high for any new biologic therapy - Capital needs are tied to long development timelines and uncertain milestones - Competitive MS and immunology pipelines could reduce commercial relevance ## Accounting For a clinical-stage biotech like Tiziana, the biggest accounting judgments are research and development expense classification, fair-value measurement of any equity-linked instruments, and the treatment of externally generated clinical or biomarker work. Because the company has limited commercial revenue, reported results are heavily shaped by period timing of development spending, stock-based compensation, and any capital-raising costs or warrant remeasurements. - **Research and development expense recognition** — Creates volatility tied to development milestones and vendor spend - **Fair value of warrants and equity instruments** — Can drive non-cash gains or losses unrelated to operations - **Accrued clinical trial costs** — Impacts liabilities and the timing of expense recognition - **Stock-based compensation** — Affects operating loss and diluted share count - R&D expense timing affects reported losses and quarterly comparability - Stock-based compensation can materially affect operating expense - Derivative or warrant valuation may create non-cash earnings volatility - Clinical study and service accruals depend on timing of vendor invoices - Capital raise costs and share issuance affect equity and EPS optics --- *Last updated: 2026-09-28T12:18:28.920661+00:00*